TNKS and pancreatic ductal adenocarcinoma: Targeting the WNT pathway with the specific tankyrase (TNKS) inhibitor, XAV-939, can enhance the immune response against pancreatic ductal adenocarcinoma (PDAC) cells with lymph node-positive metastasis [177].